Hiển thị các bài đăng có nhãn study. Hiển thị tất cả bài đăng
Hiển thị các bài đăng có nhãn study. Hiển thị tất cả bài đăng

Thứ Tư, 1 tháng 5, 2013

Britain's job market weaker than official data suggest - study

LONDON (Reuters) - A sharp rise in the number of people working less than they would like helps explain the apparent resilience of Britain's job market while the economy stagnates, according to a study published on Thursday.

British unemployment has risen from 5 percent in 2007 to just under 8 percent, well below the double-digit rates scaled during recession in the 1990s.

The study, co-authored by labour market economist and former Bank of England rate-setter David Blanchflower, shows nearly 10 percent of British workers wanted more hours than their employers would provide in 2012. In 2007, that figure stood at 5 percent, the same as the unemployment rate.

"The United States has suffered twice the increase in unemployment seen in Britain for half the drop in output," Blanchflower said. "The rise in underemployment in the UK is a big part of that puzzle."

The United States publishes a measure of underemployment which is seen as a useful indicator of slack in the economy.

Simon Kirby, UK economist at the National Institute of Economic and Social Research think-tank which published the study, urged Britain to do the same.

"Underemployment figures could be calculated easily from the existing Labour Force Survey," he said.

Britain's job market indicators may come under increasing scrutiny if the Bank follows the Federal Reserve in providing "forward guidance" on monetary policy.

The Fed has specified that rates will remain low until unemployment falls below a certain level. Chancellor George Osborne has asked the Bank to report back to him in August on the merits of adopting Fed-style guidance.

(Reporting by Christina Fincher; Editing by Ruth Pitchford)


View the original article here

Thứ Năm, 4 tháng 4, 2013

Single-director regulatory confirmations take longer: study

By Sarah N. Lynch

WASHINGTON (Reuters) - It takes about three times as long for the president and Senate to install new heads of financial regulatory agencies run by single directors as it does to approve leaders of bipartisan commissions, a study released on Thursday has found.

The study by the nonprofit Bipartisan Policy Center analyzed how long it took the president and the Senate to complete the nomination process for independent financial regulators such as Securities and Exchange Commission members and the comptroller of the currency, starting with regulators who were in office as of January 2000.

The historical trends do not bode well for Richard Cordray, President Barack Obama's pick to lead the Consumer Financial Protection Bureau, as lawmakers continue to disagree over how the new watchdog should be structured.

"We hope the analysis is useful to the ongoing conversation about the appropriate structure of independent financial regulatory agencies," said Mark Olson, who leads a working group within the center's Financial Regulatory Reform Initiative.

The study found that commission chairs take an average of seven months to be installed, with presidents taking an average of 74 days to nominate someone and the Senate taking 135 days on average to confirm a nominee.

Single-director agency heads, by contrast, take an average of two years, with the president taking an average of 439 days to nominate a candidate and the Senate an average of 229 days to confirm the nominee.

It took the Obama administration one year to nominate Cordray the first time around, and the Senate has not acted on the nomination for 623 days and counting, the report said.

Obama used a controversial recess appointment to install Cordray as head of the CFPB last year in order to bypass Senate confirmation. Republicans refused to confirm a director until Obama agreed to make changes to the bureau's structure.

Obama nominated Cordray again for a full term earlier this year. Cordray is not expected to be confirmed any time soon.

By contrast, Mary Jo White, who was chosen to head the SEC on the same day that Obama re-nominated Cordray, appears to face no clear opposition and is expected to be confirmed sometime after the Senate returns from its spring recess.

Republicans in the Senate generally like Cordray and feel he has done a good job so far. But they want the CFPB to be set up more like the SEC, with a chairman and bipartisan board.

Despite the somewhat easier process to confirm regulatory commission members, Congress in recent years has moved to create more single-director financial agencies, the report said.

In 2008, Congress combined two existing agencies into one single-head regulator, the Federal Housing Finance Agency.

Then in the 2010 Dodd-Frank law, Congress created the CFPB and the Office of Financial Research (OFR), a single-director agency within the U.S. Treasury charged with collecting and analyzing data to spot emerging risks to financial markets.

After the OFR's launch, it took Obama 513 days to nominate Richard Berner as its director and another 382 days for the Senate to confirm him, the report said.

The study also found that the nominations process for independent financial regulators has slowed under Obama compared with his predecessor, George W. Bush.

The center unveiled a new online "nominations tracker" to help the press and the public keep track of the nominations process. The tracker is available at http://bipartisanpolicy.org/nominations.

(Reporting By Sarah N. Lynch; Editing by Leslie Adler)


View the original article here

Political intelligence gathering tough to oversee: study

By David Lawder

WASHINGTON (Reuters) - Two lawmakers on Thursday renewed their bid to regulate the business of selling information gleaned from government contacts after a study said the political intelligence industry was difficult to define and would be hard to police.

Senator Charles Grassley and Representative Louise Slaughter said they would reintroduce a bill requiring political intelligence gatherers to register with the government and disclose information about their activities.

Such requirements were stripped from legislation passed last year to curb insider trading by lawmakers, their staffs and executive-branch employees.

The Stop Trading On Congressional Knowledge (STOCK) Act instead called for more study of the growing industry surrounding the collection and sale of non-public information about legislative, regulatory and executive branch matters to Wall Street investors and corporations.

The study released on Thursday by the Government Accountability Office came to few conclusions.

"The prevalence of the sale of political intelligence is not known and therefore difficult to quantify," the GAO said. "The extent to which investment decisions are based on a single piece of political intelligence would be extremely difficult to measure."

At the time the STOCK Act was being debated by Congress, Grassley, a Republican from Iowa, had suggested that the political intelligence industry could be racking up annual sales of $100 million, largely employing former congressional staffers and government officials.

Unlike lobbyists, who are subject to strict disclosure laws, people who collect information through direct, informal contacts with lawmakers, staffers and other government officials are not subject to any laws or guidelines.

The sale of such information is often bundled with industry research or policy analysis services, making it difficult to determine exactly what information clients use to make their investment decisions.

Often, multiple sources of information are combined when deciding to buy or sell securities, the study said.

"Even when a connection can be established between a discrete piece of government information and investment decisions, it is not always clear whether such information could be definitively categorized as material," the GAO said.

Still, Grassley and Slaughter, a Democratic congresswoman from upstate New York, said these professionals should be registered with the government and their activities disclosed, just like lobbyists.

"This report shows the dire need for transparency in the political intelligence industry, which profits from the cozy relationship between Washington, D.C., and Wall Street," the two lawmakers said in a statement.

WHAT IS 'DIRECT CONTACT'?

The GAO noted that insider trading laws now apply to both the executive and legislative branches of government, prohibiting officials and lawmakers from using or disclosing material non-public information for their own benefit.

Firms selling political intelligence maintain they have policies in place to ensure that they follow those laws.

If Congress chose to supplement these laws with disclosure requirements for political intelligence gatherers, it would have to deal with a lack of consensus on key definitions such as what constitutes "direct contact," or an "investment decision" or even what constitutes such intelligence, the study said.

On Capitol Hill, where information is used as currency among lawmakers, congressional staff, constituents, trade groups and the media, such requirements could make life more difficult.

The GAO said they could even prompt challenges based on perceived restrictions to free speech.

(Additional reporting by Susan Heavey; editing by Xavier Briand)


View the original article here

Thứ Ba, 2 tháng 4, 2013

Obama launches research initiative to study human brain

WASHINGTON (Reuters) - The White House unveiled details on Tuesday on a new initiative to study the human brain with the goal of treating or curing Alzheimer's disease and other disorders.

Called the Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative, the program is to be funded with $100 million from Obama's fiscal 2014 budget. The White House is slated to release Obama's budget next week.

"The BRAIN Initiative will accelerate the development and application of new technologies that will enable researchers to produce dynamic pictures of the brain that show how individual brain cells and complex neural circuits interact at the speed of thought," the White House said in a statement.

"These technologies will open new doors to explore how the brain records, processes, uses, stores and retrieves vast quantities of information, and shed light on the complex links between brain function and behavior."

(Reporting by Jeff Mason; Editing by Philip Barbara)


View the original article here

Thứ Ba, 26 tháng 2, 2013

UK study confirms GSK flu shot link to rare sleep disorder

LONDON (Reuters) - GlaxoSmithKline's Pandemrix swine flu vaccine has been linked to cases of the rare sleep disorder narcolepsy in children in a scientific study in England that confirms similar findings elsewhere in Europe.

The vaccine, more than 30 million doses of which were given during the H1N1 flu pandemic in 2009-2010, contains a booster, or adjuvant, and may have triggered an adverse immune reaction in some children at higher genetic risk of narcolepsy, scientists said in new research published on Wednesday.

Researchers at Health Protection Agency (HPA) who published the study in the British Medical Journal said the at least 14-fold increased risk they found had "implications for the future licensing and use of adjuvanted pandemic vaccines".

Narcolepsy is a life-long disorder and thought to be an autoimmune disease in which patient's immune system attacks the body's own cells. Its symptoms include frequent bouts of daytime sleepiness and in its severe forms it also causes night terrors, hallucinations and cataplexies - when strong emotions trigger a sudden loss of muscle strength.

Studies in Finland, Sweden and Ireland have also found a Pandemrix link to narcolepsy, and GSK says more than 800 cases linked to the shot have been reported in Europe.

A spokesman for the British drug maker told Reuters on Wednesday: "We really want to get to the bottom of this and understand more about the potential role of Pandemrix in the development of narcolepsy."

He added, however, that GSK believes "the available data are insufficient to assess the likelihood of a causal association between Pandemrix and narcolepsy."

As Reuters reported earlier this month, scientists investigating the link further are homing in on the vaccine's adjuvant, a booster called AS03, and analysing whether its super-charging effect may have played a role.

According to the UK results, vaccination with Pandemrix at any time was associated with a 14-fold increased risk of narcolepsy, whereas vaccination within six months before onset of the disease was associated with a 16-fold increased risk.

"The increased risk of narcolepsy indicates a causal association," said the research team led by Liz Miller, a consultant epidemiologist with the HPA. They added, however, that because of variable delay in diagnosis, the risk may be overestimated because vaccinated children may have been referred to specialist sleep clinics more rapidly.

Scientists said the risk translated into around one in 50,000, lower than studies have found in other countries such as Finland and Sweden where Pandemrix was used more widely and the risk was around one in 16,000 to 17,000 children vaccinated.

In total, more than 30 million doses of the GSK shot were given in 47 mainly European countries during the H1N1 flu pandemic. It was not used in the United States.

The UK study looked at 75 children aged between four and 18 who were diagnosed with narcolepsy from January 2008 and who attended sleep centres across England. Eleven of the children had been vaccinated with Pandemrix before their symptoms began.

Finn stressed that Pandemrix is the only vaccine linked to this problem: "There is nothing to suggest that it occurs after other flu vaccines or vaccines against other diseases."

Narcolepsy is thought to be due to loss of function in cells called hypocretin cells in one of the brain's sleep centres.

John Shneerson, a consultant physician from the Respiratory Support and Sleep Centre at Papworth Hospital in Cambridge who co-led the UK study, said Pandemrix may have triggered an immune reaction against those cells, causing narcolepsy in some children who were genetically vulnerable.

Experts say around 25 percent of Europeans have a genetic profile making them more susceptible. Narcolepsy has no known cure, but specialist doctors say symptoms can be treated with drug combinations aimed at re-regulating the sleep-wake cycle.

(Reporting by Kate Kelland; Editing by Will Waterman)


View the original article here